Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 0.50 |
| ▸ | HTR2B | P41595 | 15/20 | 0.50 |
| ▸ | HTR2A | P28223 | 13/20 | 0.50 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29841959 | 0.82 | HTR2C (0.50) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL31244837 | 0.82 | HTR2C (0.50) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL26915032 | 0.82 | HTR2C (0.50) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL30729625 | 0.82 | HTR2C (0.50) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL30565537 | 0.81 | HTR2C (0.58) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL24674699 | 0.81 | HTR2C (0.53) | HTR2CHTR2BHTR2A | |
| SCHEMBL24675535 | 0.81 | HTR2C (0.53) | HTR2CHTR2BHTR2A | |
| SCHEMBL26915186 | 0.81 | HTR2C (0.58) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL24674969 | 0.81 | HTR2C (0.53) | HTR2CHTR2BHTR2A | |
| SCHEMBL31244825 | 0.81 | HTR2C (0.59) | HTR2CHTR2BHTR2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-10-10 | — | — | US | claimed |
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| US-20240166664-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2024-05-23 | — | — | US | disclosed |
| EP-4289845-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289845-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2023-12-13 | — | — | EP | disclosed |
| CN-117083274-A | Fused ring heterocyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2022223022-A1 | FUSED-RING HETEROCYCLE DERIVATIVE AND MEDICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2022-10-27 | — | — | WO | disclosed |
| WO-2022166749-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海湃隆生物科技有限公司 | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166664-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, WEE1, WEE2 | HTR2C 4368/4885HTR2B 4434/4885HTR2A 4531/4885 |
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | PARP1, PARP2, PARP11 | HTR2C 1125/4885HTR2B 726/4885HTR2A 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.